Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers

Molecular Nutrition and Food Research

Volumn 53, Issue SUPPL. 1, 2009, Pages

  Almeida, Luis ^a,b   Vaz da Silva, Manuel ^a   Falcão, Amílcar ^c   Soares, Eva ^a   Costa, Raquel ^a   Loureiro, Ana I ^a   Fernandes Lopes, Carlos ^a   Rocha, José Francisco ^a   Nunes, Teresa ^a   Wright, Lyndon ^a   Soares da Silva, Patrício ^a,b  

^a DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^b University of Porto   (Portugal)

^c Biocant   (Portugal)

Author keywords

Bioavailability; Healthy subjects; Pharmacokinetics; Safety; Trans resveratrol

Indexed keywords

PLACEBO; RESVERATROL; STILBENE DERIVATIVE;

ADULT; ARTICLE; BIOAVAILABILITY; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; KINETICS; MALE; RANDOMIZED CONTROLLED TRIAL;

ADULT; BIOLOGICAL AVAILABILITY; CIRCADIAN RHYTHM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KINETICS; MALE; PLACEBOS; STILBENES;

EID: 67649999248     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.200800177     Document Type: Article

References (26)

1. de la Lastra, C. A., Villegas, I., Resveratrol as an anti-inflammatory and anti-aging agent: Mechanisms and clinical implications, Mol. Nutr. Food Res. 2005, 49, 405-430.
2. Fremont, L., Biological effects of resveratrol, Life Sci. 2000, 66, 663-673.
3. Bhat, K. P. L., Kosmeder, J. W., II, Pezzuto, J. M., Biological effects of resveratrol, Antioxid. Redox Signal. 2001, 3, 1041-1064.
4. Kopp, P., Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? Eur. J. Endocrinol. 1998, 138, 619-620.
5. Zhuang, H., Kim, Y. S., Koehler, R. C., Dore, S., Potential mechanism by which resveratrol, a red wine constituent, protects neurons, Ann. N Y Acad. Sci. 2003, 993, 276-286; discussion 287-278.
6. Bruno, R., Ghisolfi, L., Priulla, M., Nicolin, A., Bertelli, A., Wine and tumors: Study of resveratrol, Drugs Exp. Clin. Res. 2003, 29, 257-261.
7. Aziz, M. H., Kumar, R., Ahmad, N., Cancer prevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms, Int. J. Oncol. 2003, 23, 17-28.
8. Cal, C., Garban, H., Jazirehi, A., Yeh, C., et al., Resveratrol and cancer: Chemoprevention, apoptosis, and chemo-immunosensitizing activities, Curr. Med. Chem. Anticancer Agents 2003, 3, 77-93.
9. Delmas, D., Lancon, A., Colin, D., Jannin, B., Latruffe, N., Resveratrol as a chemopreventive agent: A promising molecule for fighting cancer, Curr. Drug Targets 2006, 7, 423-442.
10. Anekonda, T. S., Resveratrol-a boon for treating Alzheimer's disease? Brain Res. Rev. 2006, 52, 316-326.
11. Kumar, A., Kaundal, R. K., Iyer, S., Sharma, S. S., Effects of resveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy, Life Sci. 2007, 80, 1236-1244.
12. Blardi, P., DeLalla, A., Volpi, L., DiPerri, T., Stimulation of endogenous adenosine release by oral administration of quercetin and resveratrol in man, Drugs Exp. Clin. Res. 1999, 25, 105-110.
13. Boocock, D. J., Faust, G. E., Patel, K. R., Schinas, A. M., et al., Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent, Cancer Epidemiol. Biomarkers Prev. 2007, 16, 1246-1252.
14. Burkon, A., Somoza, V., Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides - two novel resveratrol metabolites in human plasma, Mol. Nutr. Food Res. 2008, 52, 549-557.
15. Soleas, G. J., Jan, J., Goldberg, D. M., Ultrasensitive assay for three polyphenols (catechin, quercetin and resveratrol) and their conjugates in biological fluids utilizing gas chromatography with mass selective detection, J. Chromatogr. B Biomed. Sci. Appl. 2001, 757, 161-172.
16. FDA/CDER, Guidance for Industry: Bioanalytical Method Validation, 2001.
17. Walle, T., Hsieh, F., DeLegge, M. H., Oatis, J. E., Jr., Walle, U. K., High absorption but very low bioavailability of oral resveratrol in humans, Drug Metab. Dispos. 2004, 32, 1377-1382.
18. Wenzel, E., Somoza, V., Metabolism and bioavailability of trans-resveratrol, Mol. Nutr. Food Res. 2005, 49, 472-481.
19. Vaz-da-Silva, M., Loureiro, A. I., Falcao, A., Nunes, T., et al., Effect of food on the pharmacokinetic profile of trans-resveratrol, Int. J. Clin. Pharmacol. Ther. 2008, 46, 564-570.
20. Vitaglione, P., Sforza, S., Galaverna, G., Ghidini, C., et al., Bioavailability of trans-resveratrol from red wine in humans, Mol. Nutr. Food Res. 2005, 49, 495-504.
21. Bruguerolle, B., Chronopharmacokinetics. Current status, Clin. Pharmacokinet. 1998, 35, 83-94.
22. Marier, J. F., Vachon, P., Gritsas, A., Zhang, J., et al., Metabolism and disposition of resveratrol in rats: Extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model, J. Pharmacol. Exp. Ther. 2002, 302, 369-373.
23. Ho, K. J., Circadian rhythmic hepatic biliary flow, constituents, concentrations and excretory rates in patients after cholecystectomy, Chronobiologia 1994, 21, 283-292.
24. Chaudhary, A., Lane, R. A., Woo, D., Herman, R. J., Multiple-dose lorazepam kinetics: Shuttling of lorazepam glucuronide between the circulation and the gut during day- and night-time dosing intervals in response to feeding, J. Pharmacol. Exp. Ther. 1993, 267, 1034-1038.
25. Maia, J., Loureiro, A. I., Fernandes-Lopes, C., Machado, R., et al., Nebicapone (BIA 3-202) pharmacokinetics following repeated administration to healthy subjects, Br. J. Clin. Pharmacol. 2007, 63, 785.
26. Wang, L. X., Heredia, A., Song, H., Zhang, Z., et al., Resveratrol glucuronides as the metabolites of resveratrol in humans: Characterization, synthesis, and anti-HIVactivity, J. Pharm. Sci. 2004, 93, 2448-2457.